Clinical analysis of inclisiran in lipid management among different risk populations with atherosclerotic cardiovascular disease
FAN Li
HAN Zhi-hua
ZHANG A-lian
XUE Chao
BIAN Ling
ZHANG Jun-feng
GU Jun
Abstract：Objective:To evaluate the lipid-lowering efficacy and safety of inclisiran in patients with atherosclerotic cardiovascular disease(ASCVD)across different risk strata.Methods:This single-center retrospective study enrolled 54 patients treated with inclisiran in the Department of Cardiology,Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine,between October 2023 and August 2024.The reduction in low density lipoprotein cholesterol(LDL-C)levels,safety profile,and goal attainment rates stratified by ASCVD risk were assessed at 3 and 9 months.Efficacy was also compared between subgroups:coronary heart disease(CHD)vs non CHD,and primary vs secondary prevention.Results:In the overall population,LDL-C reductions after 3 and 9 months of inclisiran treatment were 53.21%and 58.79%,respectively(both P<0.001).Consistent reductions were observed across all subgroups.Goal-attainment rates according to risk stratification were as follows:90.9%in the very high-risk group,55.0%in the high-risk group,66.7%in the moderate-to-high-risk group,and 78.6%in the low-risk group.Liver and kidney function indices remained stable overall,with no significant adverse reactions observed.Conclusion:Inclisiran-based combination lipid-lowering therapy demonstrates significant and safe reduction in LDL-C levels in ASCVD patients across different risk categories,with efficacy increasing over the treatment duration.
Keywords：coronary atherosclerotic heart diseaselow-density lipoprotein cholesterolinclisirangoal attainment raterisk stratification of atherosclerotic cardiovascular disease
Publication Date：2026-01-15
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：8( 64-71 )